Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability Late relapse (>5 years) of acute myeloid leukemia (AML) is rare.
1 Detecting at the time of late relapse the same genetic alteration as at diagnosis strongly suggests it may play a critical role in leukemogenesis. We previously reported in this journal that in AML with mutated nucleophosmin (NPM1), NPM1 mutation is very stable at relapse. 2 However, this conclusion was based upon molecular analysis of AML patients in whom the interval between diagnosis and relapse was short (median one year). 2 Here, we describe for the first time the clinico-pathological and molecular features of a patient with NPM1-mutated, FLT3-ITD positive AML who, after eight years, relapsed with NPM1-mutated, FLT3-ITD negative AML. These findings provide the most compelling clinical evidence to date that NPM1 mutation is stable, strongly suggesting it is a founder genetic lesion and further supporting the view that AML with mutated NPM13 is a separate entity with distinct biological and clinical features.
4,5
In May 2000, a 19-year old woman was diagnosed with acute myelo-monocytic leukemia (Online Supplementary Figures 1A) Figure 1A ), predicting NPM1 mutation. NPM1 gene sequencing showed a 4 base pair (TCTG) insertion after nucleotide 1018 corresponding to mutation A3. Molecular studies also revealed an internal tandem duplication of the FLT3 gene (FLT3-ITD) ( Figure 1B ). The number of NPM1 mutant copies assessed by quantitative PCR at diagnosis is shown in Figure 1C . Cytogenetic analysis showed a der(13;14) constitutional Robertsonian recombination associated with trisomy 4 in six metaphases and der(13;14) as the sole finding in five (data not shown).
The patient was treated under the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA)/EORTC AML12 protocol (Online Supplementary Appendix). Complete hematologic remission, first documented in June 2000, continued until May 2008 when the patient relapsed. Immunohistochemical and molecular studies confirmed nucleophosmin was dislocated into leukemic cell cytoplasm (C23/nucleolin was nucleus-restricted) (Figure 2 A, B) and NPM1 mutation A was present ( Figure 2C ). FLT3 gene analysis revealed no ITD or D835 mutations ( Figure 1B ). Cytogenetic investigation again found a 46,XX, der(13;14) (q10;q10), +4 karyotype in 4/9 metaphases ( Figure 2D ). Rescue therapy was immediately started with ARA-C, idarubicin and mylotarg (Online Supplementary Appendix). At present (September 2008), the patient is in complete hematological remission.
Our results raise interesting questions about the significance and stability of NPM1 and FLT3 mutations in AML. We previously reported an NPMc + (cytoplasmicpositive) myeloid sarcoma occurring 20 years after diagnosis of AML 7 , but no information was available on cytogenetics or NPM1 gene status of AML at presentation. In the present report, retention of NPM1 mutation-A and aberrant nucleophosmin expression in leukemic cell cytoplasm after eight years is a remarkable example of NPM1 mutation stability, which has otherwise been observed to date only in a NOD-SCID mouse model2, and strongly suggests the NPM1 mutation is needed for leukemia growth and survival. Interestingly, FLT3-ITD had disappeared at relapse, in keeping with evidence that FLT3-ITD is a secondary genetic alteration 8 that is not stable over the course of disease.
9,10
Clinical findings in this case of NPM1-mutated AML are also quite peculiar. Despite a concomitant FLT3-ITD, which usually antagonizes the favorable prognostic impact of the NPM1 mutation, 4 the patient achieved a long-lasting complete hematologic remission that was associated with an undetectable number of NPM1 mutant A copies at quantitative PCR ( Figure 1C ). This may be because a low burden of leukemic cells carried FLT3-ITD at diagnosis ( Figure 1B) . On the contrary increasing FLT3-ITD mutant levels appear to associate with a highly significant trend for worsening relapse risk and overall survival. 
Treatment of light chain deposition disease with bortezomib and dexamethasone
Light chain deposition disease (LCDD) is a rare plasma cell dyscrasia characterized by deposition of immunoglobulin fragments. The kidneys are almost always affected while heart, liver and other tissues are occasionally involved. About 50% of patients with LCDD have concurrent myeloma, however most present with nephrotic range proteinuria and rapidly deteriorating renal function.
1 Renal biopsy shows nodular glomerulosclerosis, resembling diabetic kidney changes, and linear deposits of monoclonal light chains along tubular basement membrane by immunofluorescence. The depositions are granular or amorphous and non-fibrilar, Congo-red negative.
2 The outcome of patients with LCDD is variable. Median time to end-stage renal disease (ESRD) is 2.7 years with 5-year ESRD-free survival of 37%.
2 There is no standard treatment for patients with LCDD. Chemotherapy with alkylating agents and steroids has shown modest results. 3, 4 High-dose melphalan (HDM) with autologous stem cell transplantation (ASCT) has been used in some patients and has led to improvement of renal function.
5,6
Bortezomib, a reversible proteasome inhibitor, has shown significant activity in myeloma patients and is safely administered to patients with renal failure, even those under dialysis.
7
Preliminary experience indicates that bortezomib is associated with hematologic and organ responses in patients with light chain amyloidosis.
8 Recent data indicate that this agent may have a protective role of renal parenchyma due to inhibition of NFκB activity.
9 Based on the above data we administered the combination of bortezomib and dexamethasone to 4 consecutive patients with LCDD with typical findings of renal biopsy, serum and urine electrophoresis, and immunofixation and bone marrow biopsy ( Table 1) . None of the patients had symptomatic myeloma defined by osteolytic bone disease, hypercalcemia, anemia or renal impairment due to myeloma cast nephropathy. Two patients were previously untreated; one was relapsing from prior response to cyclophosphamide with prednisone and one was refractory to vincristine, doxorubicin and dexamethasone (VAD). All patients presented with impaired renal function, non-selective proteinuria and poorly controlled hypertension, defined as blood pressure (BP) > 140/90 mmHg, although they were receiving three or more antihypertensive drugs (Table 1) . One patient also had echocardiographic evidence of heart involvement. Serum free light chains (FLCs-FREELITE assay) were elevated in all patients, with abnormal kappa to λ ratio, and were measured at the beginning of each cycle of treatment. Three patients had no measurable monoclonal
